In VivoOncology is, by far, the most lucrative market within biopharma, with Evaluate 2030 sales predictions of more than twice that of the next therapeutic area. In this contested and increasingly granular
ScripOncology is, by far, the most lucrative market within biopharma, with Evaluate 2030 sales predictions of more than twice that of the next therapeutic area. In this contested and increasingly granular
In VivoAs the pharmaceutical sector continues to evolve, the landscape of sales-driving indications is set to undergo transformation by 2030. In this article In Vivo delves into the therapeutic areas poise
ScripMEI Pharma, Inc. said on 22 July that its board of directors unanimously agreed to hire a financial consultant that can help the company assess strategic alternatives to maximize the value of its ass